Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Some of the most pressing challenges associated with interstitial lung disease (ILD) are how
best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD) …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …

Background Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing
interstitial lung disease of unknown origin. Recently, nintedanib and pirfenidone …

Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …

Background Pirfenidone is currently approved in the EU for the treatment of mild to moderate
idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there …

Pirfenidone (PFD) is a non-peptide synthetic chemical that inhibits the production of
transforming growth factor-beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), platelet …

Background Idiopathic pulmonary fibrosis (IPF) is a fatal condition with limited treatment
options. However, in a previous small study, co-trimoxazole was found to be beneficial …